The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

Telix and Regeneron Partner to Develop Advanced Prostate Cancer Therapies

Key Facts

1Telix Pharmaceuticals will evaluate its radiopharmaceutical TLX-591 in combination with Regeneron’s Libtayo.

about 2 months ago

Version History

Version 2about 2 months ago

What changed: Updated the story to include strong Q1 2026 financial results and the reaffirmation of full-year revenue guidance that exceeded market consensus.

Version 1about 2 months ago

What changed: The story was updated to include the appointment of two new Non-Executive Directors to Telix's board as part of its expansion and succession planning.

Telix Pharmaceuticals has entered into a strategic collaboration with Regeneron to evaluate a combination therapy for advanced prostate cancer, pairing its radiopharmaceutical TLX-591 with Regeneron’s Libtayo. Alongside this clinical expansion, the company reported strong Q1 2026 financial results, with revenue reaching $230M, a 24% increase year-over-year. Telix also reaffirmed its FY26 revenue guidance of $950–$970M, surpassing market consensus expectations. To support this growth, the company is strengthening its governance with the appointment of two new Non-Executive Directors effective May 2026. The stock is currently trading at a forward EV/sales multiple of 3.6x, with analysts expecting a rapid earnings inflection driven by its successful imaging franchise, including Illuccix. This dual momentum in clinical innovation and financial performance underscores Telix's robust trajectory in the oncology sector.